Share on StockTwits

Shares of Tekmira Pharmaceuticals (NASDAQ:TKMR) were the target of unusually large options trading activity on Monday. Traders acquired 10,335 put options on the stock, Analyst Ratings Network reports. This is an increase of approximately 999% compared to the typical daily volume of 940 put options.

A number of analysts have recently weighed in on TKMR shares. Analysts at Maxim Group reiterated a “hold” rating on shares of Tekmira Pharmaceuticals in a research note on Friday. They now have a $23.00 price target on the stock. Separately, analysts at Clarus initiated coverage on shares of Tekmira Pharmaceuticals in a research note on Thursday, July 31st. They set a “buy” rating and a $22.50 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $26.63.

Tekmira Pharmaceuticals (NASDAQ:TKMR) traded up 14.98% during mid-day trading on Monday, hitting $23.80. 28,391,296 shares of the company’s stock traded hands. Tekmira Pharmaceuticals has a 52 week low of $5.08 and a 52 week high of $31.48. The stock’s 50-day moving average is $12.05 and its 200-day moving average is $15.69.

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (NASDAQ:TKMR) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners.

Receive News & Ratings for Tekmira Pharmaceuticals Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tekmira Pharmaceuticals Co and related companies with Analyst Ratings Network's FREE daily email newsletter.